CAS 204656-20-2

Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with 97% homology to human GLP-1. It lowers blood glucose levels in patients with type 2 diabetes by mimicking GLP-1, stimulating insulin secretion, inhibiting glucagon, and delaying gastric emptying. It also has significant weight-loss and cardiovascular protective effects.